Extended Data Figure 10: In vivo effects of BET bromodomain inhibition in VCaP xenograft model.

a, VCaP cells were implanted subcutaneously in mice and grown until tumours reached a size of approximately 100 mm³. Xenografted mice were randomized and then received vehicle, 50 mg kg⁻¹ JQ1 or 10 mg kg⁻¹ MDV3100 5 days a week as indicated. Calliper measurements were taken twice a week. Individual tumour volumes from different treatment groups at the end of the experiments with P values are shown. b, MDV3100 treatment leads to spontaneous metastasis. Mice bearing VCaP xenografts (subcutaneously engrafted) treated with vehicle (n = 6) or MDV3100 (n = 6) were assessed for spontaneous metastasis to the femur (bone marrow) and soft tissues such as liver and spleen. Genomic DNA isolated from these sites was analysed for metastasized cells by measuring human Alu sequence (by Alu-qPCR). MDV3100-treated mice showed spontaneous metastasis to femur and liver. Spleen did not show presence of human ALU sequences. c, As in a, for mice bearing VCaP xenografts treated with vehicle (n = 6), JQ1 (n = 6) or MDV3100 (n = 6). MDV3100-treated but not JQ1-treated mice showed metastasis to femur and liver. d, JQ1 or MDV3100 treatment does not affect animal weight. Mice from VCaP cell xenograft experiments treated with vehicle, 10 mg kg⁻¹ MDV3100 or 50 mg kg⁻¹ JQ1 were weighed at the time of calliper measurements. e, Individual tumour volume for vehicle- or JQ1-treated VCaP mouse xenograft (for data shown in Fig. 4c). Mean ± s.e.m. is plotted. Statistical significance was determined by two-tailed Student’s t-test.